NCT05920850Completed
The SHARED, Project, Lung Cancer Screening for African American Men (AAM)
The SHARED Project (Testing a Lung Cancer Screening Intervention for AAM)
Source: ClinicalTrials.gov · Last updated 3 Jun 2024
Brief summary (registry, in English)
This study is a single-arm pre-test post-test design with a two-month follow-up assessment. The study aims to provide support to participants in quitting smoking and accessing lung cancer screening through the combination of education interventions and patient navigation (PN)
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 37 (actual)
- First submitted
- 17 Jun 2023
- Start date
- 14 Jul 2023
- Primary completion date
- 27 Oct 2023
- Lead sponsor
- University of Illinois Chicago
- Diseases
- Lung cancer
- NCT number
- NCT05920850
What you commit to
- Study type: Interventional
- Participants enrolled: 37
- From 14 Jul 2023 to the primary completion date, 27 Oct 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Self-report a history of lung cancer symptoms
Other
- Do not self-identify as African American males
- Former smokers
- Do not speak English
Who the study is looking for
- Self-identify as African American or Black males
- Current smokers of any nicotine-containing products
- Do not self-report a history of lung cancer symptoms
- Speaks English
Age in the registry: 50 years to 80 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Illinois Coordinator of this site? Confirm its status | Chicago | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.